Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan in Early Stage Heart Failure (VALIDATE)
NCT00241098Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2003
- Primary completion
- Jun 2005
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in Heart failure with preserved ejection fraction (HFpEF) comparing Valsartan Arm with Placebo Arm (2 arms). Primary endpoint: B-type Natriuretic Peptide at 26 weeks. Started May 2003; status: completed.
02
Drugs
valsartan
03
Conditions
Heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT00241098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00241098.